Long-term bisphosphonates: primum non nocere.

1168 Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with breast cancer: fi ndings from the Women’s Health Initiative Rebecca L. Drieling, MPH, PhD, Andrea Z. LaCroix, PhD, MPH, Shirley A.A. Beresford, PhD, MS, Denise M. Boudreau, PhD, Charles Kooperberg, PhD, Rowan T. Chlebowski, MD, PhD, Margery Gass, MD, Carolyn J. Crandall, MD, MS, Catherine R. Womack, MD, and Susan R. Heckbert, MD, PhD This study found that among women with breast cancer additional years of bisphosphonate use was associated with higher fracture risk when bisphosphonate exposure was modeled as a continuous variable in multivariate-adjusted models.